๐๐ฉ๐ซ๐ข๐ฅ ๐๐๐ฐ๐ฌ ๐๐จ๐ฎ๐ง๐ ๐๐ฉ ๐ข ๐๐ฒ๐๐๐๐ซ๐ ๐๐ฆ๐จ๐ง๐ ๐๐ก๐๐ซ๐ฆ๐โ๐ฌ ๐๐จ๐ฉ...
๐๐ฅ๐๐จ๐ง ๐๐๐ช๐ฎ๐ข๐ซ๐๐ฌ ๐๐๐ฃ๐จ๐ซ๐ข๐ญ๐ฒ ๐๐ญ๐๐ค๐ ๐ข๐ง ๐๐ฎ๐ซ๐ข๐จ๐ง ๐๐ข๐จ๐ญ๐๐๐ก ๐ญ๐จ ๐๐๐ฏ๐๐ง๐๐ ๐๐จ๐ซ๐ง๐๐๐ฅ ๐๐๐ฅ๐ฅ ๐๐ก๐๐ซ๐๐ฉ๐ฒ
๐ค Alcon has acquired a majority interest in Aurion Biotech, a clinical-stage company specialising in regenerative eye therapies. Aurionโs lead candidate, AURN001, is an allogeneic cell therapy designed to treat corneal endothelial disease, a leading cause of vision loss. The therapy has received FDA Breakthrough and Regenerative Medicine Advanced Therapy designations and is set to enter Phase 3 trials in late 2025.
๐ With this acquisition, Alcon strengthens its position in ophthalmic biopharma while advancing innovative treatments to address the global shortage of corneal tissue. Aurion will continue operating independently, leveraging Alconโs expertise and resources, with newly appointed CEO Dr. Arnaud Lacoste, PhD MBA leading its next phase of development.
